300
Participants
Start Date
March 14, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2037
thrombolysis therapy
All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.
RECRUITING
Dept. of Medicine, Baerum Hospital, Bærum
RECRUITING
Dept of Neurology, Ostfold Hospital Trust, Kalnes, Grålum
RECRUITING
Dept of Neurology, Innlandet Hospital Trust, Lillehammer, Lillehammer
RECRUITING
Dept of Neurology, Drammen Hospital Trust, Drammen
RECRUITING
Dept of Neurology, Vesfold Hospital Trust, Tonsberg, Tønsberg
RECRUITING
Dept of Neurology, Stavanger University Hospital, Stavanger
RECRUITING
Dept of Neurology, Hospital of Southern Norway, SSHF, Kristiansand
RECRUITING
Dept of Medicine, Haraldsplass deaconal Hospital, Bergen
RECRUITING
Dept. Of Neurology, Haukeland University Hopsital, Bergen
RECRUITING
Dept of Medicine, Helse More and Romsdal Health Trust, Aalesund Hospital, Ålesund
RECRUITING
Dept. Of Medicine, St.Olav Hospital, Trondheim, Trondheim
RECRUITING
Dept. of Neurology, Tromso University Hospital, Tromsø
RECRUITING
Dept. of Neurology, Oslo University Hospital, Oslo
Klinbeforsk
OTHER
Clinical Trial Unit (CTU), Oslo University Hospital
UNKNOWN
Guri Hagberg
OTHER